Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
US-10308634-B2 · Jun 4, 2019 · US
Crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
US10501437B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10501437-B2 |
| Application number | US-201716097506-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 25, 2017 |
| Priority date | Apr 29, 2016 |
| Publication date | Dec 10, 2019 |
| Grant date | Dec 10, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A hydrate of the compound of formula (I) wherein the hydrate has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value ±0.2°: 9.4, 10.8, and 15.0. 2. The hydrate of the compound of formula (I) of claim 1 , wherein the hydrate has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value ±0.2°: 9.4, 10.8, 15.0, 16.0, and 17.0. 3. The hydrate of the compound of formula (I) of claim 1 , wherein the hydrate has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value ±0.2°: 9.4, 10.8, 15.0, 16.0, 17.0, 20.1, and 22.9. 4. The hydrate of the compound of formula (I) of claim 1 , wherein the hydrate has a X-ray powder diffraction diagram at 25° C. and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value ±0.2°: 9.4, 10.8, 15.0, 16.0, 17.0, 20.1, 22.9, 24.3, 26.6, and 29.8. 5. A pharmaceutical composition comprising only a hydrate of the compound of formula (I) according to claim 1 mainly and no significant fractions of another form of the compound of formula (I). 6. A pharmaceutical composition comprising a hydrate of the compound of formula (I) according to claim 1 and pharmaceutically acceptable excipients. 7. The pharmaceutical composition of claim 6 , comprising only the hydrate of the compound of formula (I) mainly and no significant fractions of another form of the compound of formula (I). 8. The pharmaceutical composition of claim 6 , comprising the hydrate of the compound of formula (I) in more than 85 percent by weight related to the total amount of all forms of the compound of the formula (I) present in the composition. 9. The pharmaceutical composition of claim 8 , comprising the hydrate of the compound of formula (I) in more than 90 percent by weight related to the total amount of all forms of the compound of formula (I) present in the composition. 10. A method for treatment of rheumatoid arthritis in a human in need thereof, comprising administering to the human an effective amount of a hydrate of the compound of formula (I) according to claim 1 . 11. A method for treatment of rheumatoid arthritis in a human in need thereof, comprising administering to the human an effective amount of a pharmaceutical composition according to claim 5 . 12. A method for treatment of rheumatoid arthritis in a human in need thereof, comprising administering to the human an effective amount of a pharmaceutical composition according to claim 6 .
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunostimulants · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10501437B2 cover?
- The present invention relates to crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
- Who is the assignee on this patent?
- Bayer Pharma AG
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).